Mainstream Modular: Modular Construction: Here and Now

The modular construction industry has seen record growth since 2015. Once considered a lower quality and cheaper alternative to traditional construction, the industry has found a new life as a viable solution to construction needs. Tom Hardiman, executive director of the Modular Building Institute (MBI), spoke with Tyler Kern about the past, present, and future of modular construction.

As the executive director of MBI for more than 15 years, Hardiman has noticed an increase in popularity in the industry. “I’d say the state of the industry is strong. Everyone I’ve talked to said they are extremely busy. One of the busiest years they’ve had in a long not, if not the busiest year,” said Hardiman.

This rise in interest clearly has an impact on MBI as it’s the international non-profit trade association for the modular construction industry with approximately 450 member companies throughout the world. Hardiman highlighted that it’s a “portal or hub for anyone who wants information on modular construction.”

Being isolated from the traditional construction industry during the 2000s, the industry has faced some challenge. However, since 2015, there has been a dramatic change and a greater need for modular and hybrid projects. In the past five years alone, MBI has doubled its membership and the industry has doubled its market share.

These numbers illustrate that many of the misconceptions around quality have dissolved. Although some still believe it’s cheaper than traditional construction, there are still the same costs associated like local labor rates, local material rates, labor availability, and the experience of the team. However, the significant time savings and labor efficiencies associated with module construction should lead to lower overall costs.

Listen in to hear more about the exciting developments within the modular construction industry, and don’t miss seeing Hardiman as a guest speaker at the 2022 World of Modular Annual Convention and Tradeshow in San Antonio, TX from April 25–28.

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More